

Abdominal aortic aneurysm: diagnosis and management

**Evidence review C: Risk factors associated with
abdominal aortic aneurysm growth or rupture**

NICE guideline NG156

Methods, evidence and recommendations

March 2020

Final

*This evidence review was developed by
the NICE Guideline Updates Team*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2020. All rights reserved. Subject to [Notice of rights](#).

ISBN: 978-1-4731-3452-2

Contents

Risk factors associated with abdominal aortic aneurysm growth or rupture	5
Review question	5
Introduction	5
PICO table.....	5
Methods and process	6
Clinical evidence	6
Summary of clinical studies included in the evidence review	7
Quality assessment of clinical studies included in the evidence review	8
Economic evidence	8
Excluded studies	9
Evidence statements for aneurysm growth	9
Evidence statements for aneurysm rupture	10
The committee’s discussion of the evidence.....	11
Appendices	14
Appendix A – Review protocols	14
Review protocol for risk factors associated with aneurysm growth or rupture.	14
Appendix B – Literature search strategies	16
Clinical search literature search strategy	16
Health Economics literature search strategy.....	17
Appendix C – Clinical evidence study selection	19
Appendix D – Clinical evidence tables	20
Appendix E – GRADE tables	31
Risk factors associated with aneurysm growth	31
Risk factors associated with aneurysm rupture.....	39
Appendix F – Economic evidence study selection	42
Appendix G – Excluded studies.....	43
Clinical studies	43
Economic studies	48
Appendix H – Glossary.....	49

Risk factors associated with abdominal aortic aneurysm growth or rupture

Review question

What risk factors are associated with abdominal aortic aneurysm a) expansion and b) rupture?

Introduction

The management of small abdominal aortic aneurysms (AAA) vary considerably. An important aspect of management of AAAs is understanding how often people should be monitored for aneurysm growth. Furthermore, it is important to identify which patients are more likely to experience aneurysm rupture. As a result, this review question aims to determine which risk factors (or combinations of these) may suggest the need for more frequent monitoring of patients with AAA and inform the decision about when to offer intervention.

PICO table

Table 1: Inclusion criteria

Parameter	Inclusion criteria
Population	People with a confirmed AAA >3cm in diameter Stratified by aneurysm diameter, age, sex, comorbidities
Index test / factors of interest	<ul style="list-style-type: none"> • Aneurysm size (different approaches to measurement) • Abdominal pain • Back pain • Abdominal palpation • Pulsatile abdominal mass/pulsation • Age • Sex • Other cardiovascular disease (existing or previous) – other aneurysms, atherosclerotic disease, vascular claudication • Inflammatory disease • Smoking • Blood pressure/hypertension • Dislipidaemia • Hypercholesterolaemia • Family history of AAAs, other aneurysms, collagen disorders • Ethnicity • Diabetes • COPD • BMI/weight/obesity • Chemotherapy • Other surgery, particularly abdominal or urological • Finite element method rupture index (FEARI) (risk of rupture based on geometry, blood pressure, gender-specific wall strength) • Stiffness of the aorta (pulse wave velocity = surrogate marker) • AAA wall stress

Parameter	Inclusion criteria
	<ul style="list-style-type: none"> • Vessel asymmetry • Rupture potential index (RPI) • Severity parameter (SP) • Growth of intraluminal thrombus • Rate of expansion
Endpoints	<ul style="list-style-type: none"> • Radiological diagnosis of AAA expansion; single test within a study • Surgically- or radiologically-confirmed rupture of an AAA

Methods and process

This evidence review was developed using the methods and process described in [Developing NICE guidelines: the manual](#). Methods specific to this review question are described in the review protocol in Appendix A.

Declarations of interest were recorded according to NICE's 2014 conflicts of interest policy.

A single broad search was used to identify all studies that examine the diagnosis, surveillance or monitoring of AAAs. This was a 'bulk' search that covered multiple review questions. The database was sifted to identify all studies that met the criteria detailed in Table 1. The relevant review protocol can be found in Appendix A.

Prospective observational studies that explored the association between potential risk factors and the occurrence of aneurysm growth or rupture, using multivariate logistic regression or Cox regression were considered for inclusion. Ideally, prospective cohort studies with sample sizes of more than 500 participants were included. In the absence of prospective cohort studies, retrospective cohort studies in which **all** individuals in a cohort were followed up to examine whether they developed aneurysm growth or rupture, were included. For example, all patients included in a disease register or screening programme, established in the past, who were followed up prospectively.

Studies were excluded if they:

- were case-controls or cross-sectional studies
- were not in English
- were not full reports of the study (for example, published only as an abstract)
- were not peer-reviewed.

Clinical evidence

Included studies

From a database of 16,274 abstracts, 41 were identified as being potentially relevant. Following full-text review of these articles, 6 studies were included. These included 2 prospective cohort studies, 3 retrospective cohort studies and 1 individual patient data (IPD) meta-analysis which did not include data from any of the other studies which have been included individually. The IPD meta-analysis was considered as 1 large cohort study on the basis that analysis was performed pooling data from individual patients, as opposed to pooling study level data.

An update literature search was performed and provided by Cochrane, in December 2017. The search found a total of 2,180 abstracts; of which, 9 full manuscripts were

ordered. Upon review of the full manuscripts, none of the studies met the inclusion criteria for this review question.

Excluded studies

The list of papers excluded at full-text review, with reasons, is given in Appendix G.

Summary of clinical studies included in the evidence review

A summary of the included studies is included in the table below.

Table 2: Summary of included studies

Study	Details
Brown L C, and Powell J T (1999) Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. <i>Annals of surgery</i> 230(3), 289-96; discussion 296-7	Study design: Prospective cohort study Location(s): UK Population: Adults, between 60 and 76 years with AAAs between 4.0 and 5.5 cm in diameter Sample size: 2,557 Outcome: Aneurysm rupture Risk factors: Age; sex; initial AAA diameter (cm); smoking status; body mass index (BMI); mean blood pressure (mmHG); ankle-brachial pressure index measurement; forced expiratory volume in 1 second (FEV1); cholesterol (mmol/L)
Ferguson Craig D, Clancy Paula, Bourke Bernard, Walker Philip J, Dear Anthony, Buckenham Tim, Norman Paul, and Golledge Jonathan (2010) Association of statin prescription with small abdominal aortic aneurysm progression. <i>American heart journal</i> 159(2), 307-13	Study design: Prospective cohort study Location(s): Australia and New Zealand Population: People with AAAs between 3.0 and 5.0 cm in diameter Sample size: 652 Outcome: Aneurysm growth Risk factors: Age; sex; diabetes; hypertension; coronary heart disease; peripheral artery disease; smoking status; initial aortic diameter; taking ACE inhibitors; taking aspirin; taking beta-blockers; taking statins
Nakayama Atsuko, Morita Hiroyuki, Miyata Tetsuro, Ando Jiro, Fujita Hideo, Ohtsu Hiroshi, Akai Takafumi, Hoshina Katsuyuki, Nagayama Masatoshi, Takanashi Shuichiro, Sumiyoshi Tetsuya, and Nagai Ryoza (2012) Inverse association between the existence of coronary artery disease and progression of abdominal aortic aneurysm. <i>Atherosclerosis</i> 222(1), 278-83	Study design: Retrospective cohort study Location(s): Japan Population: People with AAAs greater than 5 cm in diameter Sample size: 665 Outcome: Aneurysm growth Risk factors: Age; sex; BMI; hypertension; dyslipidaemia; diabetes; smoking status; haemodialysis; creatine levels (mg/dL); family history of AAA; family history of coronary artery disease; existence of preoperative coronary artery disease; ischaemic changes on ECG; presence of cerebral artery disease; presence of COPD; taking beta-blockers; taking ACE inhibitors; taking calcium-channel blockers; taking statins
Norman Paul, Spencer Carole A, Lawrence-Brown Michael M, and Jamrozik Konrad (2004) C-reactive protein levels and the expansion of screen-detected	Study design: Retrospective cohort study Location(s): USA Population: Men, between 65 and 83 years, with small AAAs (size range not specified)

Study	Details
abdominal aortic aneurysms in men. <i>Circulation</i> 110(7), 862-6	Sample size: 545 Outcome: Aneurysm growth Risk factors: Initial aorta size; smoking status; C-reactive protein levels (mg/L)
Santilli S M, Littooy F N, Cambria R A, Rapp J H, Tretinyak A S, d'Audiffret A C, Kuskowski M A, Roethle S T, Tomczak C M, and Krupski W C (2002) Expansion rates and outcomes for the 3.0-cm to the 3.9-cm infrarenal abdominal aortic aneurysm. <i>Journal of vascular surgery : official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, and North American Chapter</i> 35(4), 666-671	Study design: Retrospective cohort study Location(s): Australia Population: All people with AAAs between 3.0 and 3.9 cm in diameter who were screened for the ADAM randomised controlled trial. Sample size: 790 Outcome: Aneurysm growth Risk factors: initial infrarenal aortic diameter; age; family history of AAA; smoking status; cardiovascular disease (history of angina, stroke, myocardial infarction, or coronary artery bypass grafting); claudication; diabetes; hypertension (previous diagnosis or current medication); or hypercholesterolemia (previous diagnosis or current medication)
Thompson S G, Brown L C, Sweeting M J, Bown M J, Kim L G, Glover M J, Buxton M J, and Powell J T (2013) Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness. <i>Health technology assessment (Winchester, and England)</i> 17(41), 1-118	Study design: Individual patient data meta-analysis Location(s): UK Population: People with AAAs between 3.0 and 5.5 cm in diameter Sample size: 15,475 Outcome: Aneurysm growth and aneurysm rupture. Note that data on aneurysm growth was not extracted as analysis compared linear aneurysm growth rates (continuous variable) using linear regression. Risk factors: Age; sex; smoking status; BMI; diabetes; mean arterial blood pressure (per 10 mmHg); pulse pressure (per 10 mmHg); history of cardiovascular disease

See Appendix D for full evidence tables.

Quality assessment of clinical studies included in the evidence review

See Appendix E for full GRADE tables, highlighting the quality of evidence from the included studies

Economic evidence

Included studies

A literature search was conducted jointly for all review questions by applying standard health economic filters to a clinical search for AAA. This search returned a total of 5,173 citations. Following review of all titles and abstracts, no studies were identified as being potentially relevant to risk factors associated with AAA expansion or rupture. No full texts were retrieved, and so no studies were included as economic evidence.

An update search was conducted in December 2017, to identify any relevant health economic analyses published during guideline development. The search found 814

abstracts; all of which were not considered relevant to this review question. As a result no additional studies were included.

Excluded studies

No studies were retrieved for full-text review.

Evidence statements for aneurysm growth

History of cardiovascular disease

Very low-quality evidence from a retrospective cohort study, including 665 people with AAA, could not differentiate aneurysm growth between people with and without a family history of cardiovascular disease. Conversely, low- to high-quality evidence from 1 retrospective cohort study and 1 prospective cohort study, including up to 665 people with AAA, indicated that people with coronary artery disease were less likely to experience aneurysm growth than those without coronary artery disease.

Hypertension

Very low- to moderate-quality evidence from 1 retrospective cohort study and 1 prospective cohort study, including up to 665 people with AAA, could not differentiate aneurysm growth between people with and without hypertension. Conversely, very low-quality evidence from 1 retrospective cohort study, including 790 people with AAA, indicated that people with hypertension were more likely to experience aneurysm growth than those without hypertension.

Diabetes

Very low-quality evidence from 1 retrospective cohort study, including 665 people with AAA, could not differentiate aneurysm growth between people with and without diabetes. Conversely, very low- to high-quality evidence from 1 retrospective cohort study and 1 prospective cohort study, including up to 790 people with AAA, indicated that people with diabetes were less likely to experience aneurysm growth than those without diabetes.

Claudication

Very low-quality evidence from 1 retrospective cohort study, including 790 people with AAA, indicated that people with claudication were less likely to experience aneurysm growth than those without claudication.

Initial aneurysm diameter

Moderate- to high-quality evidence from 1 retrospective cohort study and 1 prospective cohort study, including up to 652 people with AAA, indicated that increasing aneurysm diameters, at the time of diagnosis, increased the odds of aneurysm growth.

Medication use

Very low- to moderate-quality evidence from 1 retrospective cohort study and 1 prospective cohort study, including up to 665 people with AAA, aspirin, beta-blocker, ace inhibitor, angiotensin receptor blocker, calcium-channel blocker or statin use had no impact on aneurysm growth. Moderate-quality evidence from 1 retrospective

cohort study, including 665 people with AAA, indicated that people taking statins had lower odds of aneurysm growth than those who were not taking statins.

Other potential risk factors

Very low- to moderate-quality evidence from 1 retrospective cohort study and 1 prospective cohort study, including up to 665 people with AAA, could not identify any associations between the following factors and aneurysm growth:

- Age
- Sex
- Smoking status
- BMI
- A family history of AAA
- Presence of COPD
- Presence of peripheral artery disease
- Presence of cerebral artery disease
- Presence of dyslipidaemia
- Ischaemic changes on ECG
- Haemodialysis
- Creatinine levels

Evidence statements for aneurysm rupture

Age

Moderate-quality evidence from 1 prospective cohort study, including 2,256 people with AAA, could not find any association between increasing age and aneurysm rupture. Conversely, low-quality evidence from 1 individual patient data meta-analysis, including 15,745 people with AAA, indicated that increasing age increased the odds of aneurysm rupture.

Sex

High-quality evidence from 1 prospective cohort study, including 2,256 people with AAA, indicated that women were more likely than men to experience aneurysm rupture. Additional low-quality evidence from 1 individual patient data meta-analysis, including 15,745 people with AAA, highlighted that women were more likely to experience aneurysm rupture than men.

Smoking status

Moderate- to high-quality evidence from 1 prospective cohort study, including 2,242 people with AAA, indicated that ex-smokers were less likely to experience aneurysm rupture than current smokers. The same study reported that people who never smoked were less likely to experience rupture than current smokers; however, the differences between groups were not significant. Low-quality evidence from 1 individual patient data meta-analysis, including 15,745 people with AAA, highlighted that current smokers were more likely experience aneurysm rupture than ex-smokers or those who never smoked.

BMI

Moderate-quality evidence from 1 prospective cohort study, including 2,242 people with AAA, could not differentiate aneurysm rupture rates of people with different BMI measurements. Conversely, low-quality evidence from 1 individual patient data meta-analysis, including 15,745 people with AAA, indicated that increasing BMI decreased the odds of aneurysm rupture.

Diabetes

Very low-quality evidence from 1 individual patient data meta-analysis, including 15,475 people with AAA, could not differentiate aneurysm rupture rates of people with and without diabetes.

Blood pressure

Low-quality evidence from 1 individual patient data meta-analysis, including 15,475 people with AAA, highlighted that both increasing arterial blood pressure and increasing pulse pressure increased the odds of aneurysm rupture. High-quality evidence from 1 prospective cohort study, including 2,146 people with AAA, could not differentiate aneurysm rupture rates of people with different ankle–brachial pressure index measurements.

Cholesterol levels

Moderate-quality evidence from 1 prospective cohort study, including 2,107 people with AAA, could not differentiate aneurysm rupture rates in people with different cholesterol level measurements.

History of cardiovascular disease

Very low-quality evidence from 1 individual patient data meta-analysis, including 15,475 people with AAA, could not differentiate aneurysm rupture rates between people with and without a history of cardiovascular disease.

Initial aneurysm diameter

High-quality evidence from 1 prospective cohort study, including 2,257 people with AAA, indicated that increasing aneurysm diameters, at the time of diagnosis, increased the odds of aneurysm rupture.

The committee's discussion of the evidence.**Interpreting the evidence*****The outcomes that matter most***

The committee considered various types of risk factors, including modifiable and non-modifiable risk factors. It was agreed that modifiable risk factors mattered most as they would support people with AAA to decrease their chances of experiencing aneurysm growth or rupture.

The quality of the evidence

The committee noted that the quality of evidence ranged from very low to high. Evidence from retrospective cohort studies was considered lower in quality than that

of prospective cohort studies because of the inability to accurately monitor confounders during follow-up. Nakayama et al. (2012) was considered to be at high risk of selection bias because the study population only comprised people who underwent surgery. This means that data from patients who had growing aneurysms which did not reach the threshold for surgical repair or patients who opted not to receive intervention would not have been considered in any analyses. The study by Santilli et al. (2002) was considered to be prone to responder bias because participants were asked to complete a brief questionnaire asking whether they had ever been told by a physician that they had any risk factors of interest.

The committee noted that statistical heterogeneity (I^2) ranged from 0 to 98% in the IPD meta-analysis by Thompson et al. (2013). There was some variation in baseline AAA diameters across included studies, making comparisons between the studies difficult. Furthermore, there was some heterogeneity in the imaging techniques and parameters used in included studies in the meta-analysis. Most studies from which data were obtained used ultrasound imaging to measure aneurysm diameters; however, a few of the studies used CT. Some studies measured external (outer-to-outer) wall diameters, whereas others measured internal diameters. Finally, study-specific thresholds for surgical intervention varied from 4.5 cm up to 6.0 cm.

The committee suspected that atheromatous coronary artery disease would be associated with aneurysm growth and was surprised that the identified evidence indicated that coronary artery disease may decrease the odds of growth. It was noted that the studies did not specify the nature of the coronary artery disease. Therefore, in the absence of this information, the committee refrained from making any recommendations.

Benefits and harms

The committee noted that the identified evidence highlighted no association between the following factors and the occurrence of aneurysm growth: increasing age, sex, BMI and a family history of AAA. The committee noted that the majority of these factors were non-modifiable and interpreted the evidence as an indication that little could be done in relation to these factors to alter the course of aneurysm growth.

The committee agreed to focus recommendations on modifiable risk factors associated with aneurysm growth or rupture because targeting these factors would help people with AAA to decrease the chances of aneurysm growth or rupture.

Evidence from the IPD meta-analysis identified being a current smoker as a clear predictor of risk of aneurysm rupture. This was supported by evidence from the prospective cohort study by Brown et al. (2013) which indicated that ex-smokers are less likely to experience aneurysm rupture than current smokers. The committee therefore agreed that smoking cessation was likely to reduce the odds of rupture.

The committee discussed the evidence suggesting that women are approximately 3 times more likely to experience AAA rupture than men; however, it was noted that there is currently no published evidence indicating that women with AAA should be treated differently to men with AAA. The committee were aware that there is ongoing observational research (in the form of cohort studies) on aneurysms in women which might inform sex-specific recommendations in the future.

Cost effectiveness and resource use

The committee considered that a cross-referral to NICE Public Health guidance relating to stop smoking services was unlikely to have a direct impact on costs. This is because current practice already outlines that all people who smoke should be

offered access to a stop smoking service. The committee noted that not all clinicians are able to provide smoking cessation advice but there is usually an avenue to refer patients on to a stop smoking service.

Other factors the committee took into account

The committee agreed that referral pathways to hypertension management services between primary and secondary vary across the NHS. As a result, it was considered that the recommendation would help address the variability. The committee believed that specifying which clinicians should provide hypertension management services would be too prescriptive. As a result, it was decided that a cross-referral to existing NICE guidance was appropriate.

Upon consideration of the evidence highlighting that women had a higher risk of experiencing aneurysm rupture than men, the committee discussed whether it was possible to make recommendations specific to monitoring of women. They agreed that it was not possible to specify shorter follow-up intervals in women without evidence to support such a recommendation. The committee noted that they made a research recommendation, in a separate review assessing thresholds for surgery, which explicitly mentioned that subgroup analyses should be stratified by sex to determine whether sex-specific monitoring frequencies are possible. As a result, the committee decided not to make a recommendation until additional evidence is available.

Appendices

Appendix A – Review protocols

Review protocol for risk factors associated with aneurysm growth or rupture.

Review question 3	What risk factors are associated with abdominal aortic aneurysm a) expansion and b) rupture?
Objectives	To determine which risk factors (or combinations of these) may suggest the need for more frequent monitoring of patients with AAA, and to inform management decisions
Type of review	Prognostic
Language	English
Study design	i) Prospective observational studies using multivariate analysis; population >500 ii) Multivariate analysis of UK registry data (National Abdominal Aortic Aneurysm Screening Programme)
Status	i) Published papers only (full text) No date restrictions ii) Expert witness to present findings from UK registry data
Population	People with a confirmed abdominal aortic aneurysm >3cm in diameter Subgroups: by aneurysm diameter, age, sex, comorbidities
Index test / factors of interest	Aneurysm size (different approaches to measurement) Abdominal pain Back pain Abdominal palpation Pulsatile abdominal mass/pulsation Age Sex Other cardiovascular disease (existing or previous) – other aneurysms, atherosclerotic disease, vascular claudication Inflammatory disease Smoking Blood pressure/hypertension Dislipidaemia Hypercholesterolaemia Family history of abdominal aortic aneurysms, other aneurysms, collagen disorders Ethnicity Diabetes COPD BMI/weight/obesity Chemotherapy Other surgery, particularly abdominal or urological Finite element method rupture index (FEARI) (risk of rupture based on geometry, blood pressure, gender-specific strength of wall) Stiffness of the aorta (pulse wave velocity = surrogate marker) AAA wall stress Vessel asymmetry Rupture potential index (RPI) Severity parameter (SP)

Review question 3	What risk factors are associated with abdominal aortic aneurysm a) expansion and b) rupture?
	Growth of intraluminal thrombus Rate of expansion
Endpoint	Radiological diagnosis of abdominal aortic aneurysm expansion; single test within a study Surgically- or radiologically-confirmed rupture of an abdominal aortic aneurysm
Other criteria for inclusion / exclusion of studies	Exclusion: Non-English language Abstract/non-published (i only)
Baseline characteristics to be extracted in evidence tables	Age Sex Size of aneurysm Comorbidities
Search strategies	See Appendix B
Review strategies	<p>i) Double-sifting of randomly selected 20%. Appropriate NICE Methodology Checklists, depending on study designs, will be used as a guide to appraise the quality of individual studies. 20% will be appraised by a second reviewer.</p> <p>Available Cochrane review (Filardo, 2015) will be used as a 'seed review'; studies published since 2014 and studies with outcomes of interest not reported in the Cochrane review will be added</p> <p>Data on all included studies will be extracted into evidence tables. Where statistically possible, a meta-analytic approach will be used to give an overall summary effect.</p> <p>All key findings from evidence will be presented in GRADE profiles.</p> <p>ii) Expert witnesses will attend a Committee meeting to answer questions from members of the Committee. They will be invited to present their evidence at a Committee meeting in the form of expert testimony based on a written paper. The Developer will write up the expert testimony and agree this with the witness after the meeting.</p> <p>i and ii) All key findings will be summarised in evidence statements.</p>
Key papers	<p>Bhak,Rachel H., Winger,Michael, Johnson,Gary R., Lederle, Frank A., Messina,Louis M., Ballard,David J., Wilson,Samuel E.. Factors associated with small abdominal aortic aneurysm expansion rate. JAMA Surg 2015;150(1):44-50</p> <p>Thompson SG, Brown LC, Sweeting MJ, Bown MJ, Kim LG, Glover MJ, Buxton MJ, Powell JT. Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness. Health Technol Assess. 2013 Sep;17(41):1-118</p>

Appendix B – Literature search strategies

Clinical search literature search strategy

Main searches

Bibliographic databases searched for the guideline

- Cumulative Index to Nursing and Allied Health Literature - CINAHL (EBSCO)
- Cochrane Database of Systematic Reviews – CDSR (Wiley)
- Cochrane Central Register of Controlled Trials – CENTRAL (Wiley)
- Database of Abstracts of Reviews of Effects – DARE (Wiley)
- Health Technology Assessment Database – HTA (Wiley)
- EMBASE (Ovid)
- MEDLINE (Ovid)
- MEDLINE Epub Ahead of Print (Ovid)
- MEDLINE In-Process (Ovid)

Identification of evidence for review questions

The searches were conducted between November 2015 and October 2017 for 31 review questions (RQ). In collaboration with Cochrane, the evidence for several review questions was identified by an update of an existing Cochrane review. Review questions in this category are indicated below. Where review questions had a broader scope, supplement searches were undertaken by NICE.

Searches were re-run in December 2017.

Where appropriate, study design filters (either designed in-house or by McMaster) were used to limit the retrieval to, for example, randomised controlled trials. Details of the study design filters used can be found in section 4.

Search strategy review question 3

Medline Strategy, searched 29th September 2016

Database: 1946 to September Week 3 2016

Search Strategy:

- 1 Aortic Aneurysm, Abdominal/
- 2 Aortic Rupture/
- 3 (aneurysm* adj4 (abdom* or thoracoabdom* or thoraco-abdom* or aort* or spontan* or juxtarenal* or juxta-renal* or juxta renal* or paraarenal* or para-renal* or para renal* or suprarenal* or supra renal* or supra-renal* or short neck* or short-neck* or shortneck* or visceral aortic segment*)).tw.
- 4 or/1-3
- 5 prognosis.sh.
- 6 diagnosed.tw.
- 7 cohort.mp.
- 8 predictor:.tw.
- 9 death.tw.
- 10 exp models, statistical/
- 11 or/5-10

Medline Strategy, searched 29th September 2016**Database: 1946 to September Week 3 2016****Search Strategy:**

```

12 (sensitiv: or predictive value:).mp. or accurac:.tw.
13 11 or 12
14 "signs and symptoms"/
15 ((sign or signs) adj5 symptom*).tw.
16 Risk Factors/
17 factor*.tw.
18 predict*.tw.
19 or/14-18
20 13 or 19
21 4 and 20
22 animals/ not humans/
23 21 not 22 (12444)
24 limit 23 to english language

```

Health Economics literature search strategy**Sources searched to identify economic evaluations**

- NHS Economic Evaluation Database – NHS EED (Wiley) last updated Dec 2014
- Health Technology Assessment Database – HTA (Wiley) last updated Oct 2016
- Embase (Ovid)
- MEDLINE (Ovid)
- MEDLINE In-Process (Ovid)

Search filters to retrieve economic evaluations and quality of life papers were appended to the population and intervention terms to identify relevant evidence. Searches were not undertaken for qualitative RQs. For social care topic questions additional terms were added. Searches were re-run in September 2017 where the filters were added to the population terms.

Health economics search strategy**Medline Strategy**

```

Economic evaluations
1 Economics/
2 exp "Costs and Cost Analysis"/
3 Economics, Dental/
4 exp Economics, Hospital/
5 exp Economics, Medical/
6 Economics, Nursing/
7 Economics, Pharmaceutical/
8 Budgets/
9 exp Models, Economic/
10 Markov Chains/
11 Monte Carlo Method/
12 Decision Trees/
13 econom*.tw.
14 cba.tw.

```


Medline Strategy

15 cea.tw.
 16 cua.tw.
 17 markov*.tw.
 18 (monte adj carlo).tw.
 19 (decision adj3 (tree* or analys*)).tw.
 20 (cost or costs or costing* or costly or costed).tw.
 21 (price* or pricing*).tw.
 22 budget*.tw.
 23 expenditure*.tw.
 24 (value adj3 (money or monetary)).tw.
 25 (pharmacoeconomic* or (pharmaco adj economic*)).tw.
 26 or/1-25

Quality of life

1 "Quality of Life"/
 2 quality of life.tw.
 3 "Value of Life"/
 4 Quality-Adjusted Life Years/
 5 quality adjusted life.tw.
 6 (qaly* or qald* or qale* or qtime*).tw.
 7 disability adjusted life.tw.
 8 daly*.tw.
 9 Health Status Indicators/
 10 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty six).tw.
 11 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
 12 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
 13 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form sixteen).tw.
 14 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form twenty).tw.
 15 (euroqol or euro qol or eq5d or eq 5d).tw.
 16 (qol or hql or hqol or hrqol).tw.
 17 (hye or hyes).tw.
 18 health* year* equivalent*.tw.
 19 utilit*.tw.
 20 (hui or hui1 or hui2 or hui3).tw.
 21 disutili*.tw.
 22 rosser.tw.
 23 quality of wellbeing.tw.
 24 quality of well-being.tw.
 25 qwb.tw.
 26 willingness to pay.tw.
 27 standard gamble*.tw.
 28 time trade off.tw.
 29 time tradeoff.tw.
 30 tto.tw.
 31 or/1-30

Appendix C – Clinical evidence study selection



Appendix D – Clinical evidence tables

Full citation	Brown L C, and Powell J T (1999) Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Annals of surgery 230(3), 289-96; discussion 296-7
Study details	<p>Study design: Prospective cohort study</p> <p>Location(s): UK</p> <p>Aim of the study: To investigate risk factors associated with aneurysm rupture.</p> <p>Study dates: 1991 to 1998</p> <p>Follow-up: 3 years</p> <p>Sources of funding: The trial was supported by grants from the UK Medical Research Council, the British Hearth Foundation.</p>
Participants	<p>Sample size: 2,557</p> <p>Inclusion criteria: People with AAAs between, 60 and 76 years, who were entered into either UKSAT trial or the “Small Aneurysm Study”. Patients who were eligible for randomisation into the trials had aneurysm diameters between 4.0 and 5.5 cm. Patients who were ineligible for randomisation into the trials were also included. These patients were ineligible if they had an AAA diameter < 4.0 cm or > 5.5 cm, if they refused randomisation or if surgery was considered unsuitable.</p> <p>Exclusion criteria: Not specified</p>
Methods	<p>Data collection: Patients were assessed by a clinical interview and physical examination to collect data on risk factors. The maximum antero-posterior diameter of aneurysms was determined using ultrasound imaging: imaging intervals were not specified.</p> <p>Analysis: Cox regression analysis, adjusting for age, sex and initial AAA diameter.</p> <p>Baseline characteristics:</p> <ul style="list-style-type: none"> • Mean age: 69 years • Sex: 79.4% male • Mean aneurysm diameter: 4.6 cm • History of diabetes: 4.4% • History of hypertension: 41.2%
Outcomes	<p>Outcome: Aneurysm rupture (ascertained either from a death certificate or from ultrasound imaging)</p> <p>Risk factors: Age; sex; initial AAA diameter (cm); smoking status; body mass index (BMI); mean blood pressure (mmHG); ankle-brachial pressure index measurement; forced expiratory volume in 1 second (FEV₁); total cholesterol (mmol/L)</p>
Risk of bias assessment	1. Did the study address a clearly focused issue? Yes

Full citation	Brown L C, and Powell J T (1999) Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Annals of surgery 230(3), 289-96; discussion 296-7
(using CASP tool)	<p>2. Was the cohort recruited in an acceptable way? Yes</p> <p>3. Was the exposure accurately measured to minimise bias? Yes - measured in accordance of UKSAT trial protocols</p> <p>4. Was the outcome accurately measured to minimise bias? Yes</p> <p>5 (a) Have the authors identified all important confounding factors? Unclear (b) Have they taken account of the confounding factors in the design and/or analysis? Unclear</p> <p>6 (a) Was the follow up of subjects complete enough? Yes (b) Was the follow up of subjects long enough? Yes</p> <p>Overall risk of bias: Low</p> <p>Directness: directly applicable</p>
Full citation	Ferguson Craig D, Clancy Paula, Bourke Bernard, Walker Philip J, Dear Anthony, Buckenham Tim, Norman Paul, and Golledge Jonathan (2010) Association of statin prescription with small abdominal aortic aneurysm progression. American heart journal 159(2), 307-13
Study details	<p>Study design: Prospective cohort study</p> <p>Location(s): Australia and New Zealand</p> <p>Aim of the study: To assess the association between statin usage and AAA growth.</p> <p>Study dates:</p> <p>Follow-up: Median of 5 years</p> <p>Sources of funding: Grants were received from the National Institute of Health (USA), Townsville Hospital Private Practice Fund, National Heart Foundation and National Health and Medical Research Council.</p>
Participants	<p>Sample size: 652</p> <p>Inclusion criteria: People with small AAAs between 3.0 and 5.0 cm in diameter for whom the recruiting clinician had no plan to perform surgical repair.</p> <p>Exclusion criteria: Not specified</p> <p>Baseline characteristics:</p> <ul style="list-style-type: none"> • Mean age: 73 years • Sex: 94% male • Mean aneurysm diameter: 3.3 cm • Diabetes: 13%

Full citation	Ferguson Craig D, Clancy Paula, Bourke Bernard, Walker Philip J, Dear Anthony, Buckenham Tim, Norman Paul, and Golledge Jonathan (2010) Association of statin prescription with small abdominal aortic aneurysm progression. American heart journal 159(2), 307-13
	<ul style="list-style-type: none"> • Hypertension: 60% • Coronary heart disease: 46% • Peripheral arterial disease: 20%
Methods	<p>Data collection: Patients were assessed by a clinical interview and physical examination plus their medical records were reviewed to collect data on risk factors. The maximum antero-posterior diameter of aneurysms was determined using ultrasound imaging performed at 6 month intervals (for aneurysms 4.5 to 5.0 cm in diameter) or yearly intervals (for aneurysms 3.0 to 4.4 cm in diameter).</p> <p>Analysis: Multivariate logistic regression, adjusting for initial aortic diameter presence of diabetes, and presence of coronary heart disease</p>
Outcomes	<p>Outcome: Aneurysm growth (binary outcome)</p> <p>Risk factors: Age; sex; diabetes; hypertension; coronary heart disease; peripheral artery disease; smoking status; initial aortic diameter; taking ACE inhibitors; taking aspirin; taking beta-blockers; taking statins</p>
Risk of bias assessment (using CASP tool)	<ol style="list-style-type: none"> 1. Did the study address a clearly focused issue? Yes 2. Was the cohort recruited in an acceptable way? Yes 3. Was the exposure accurately measured to minimise bias? Yes 4. Was the outcome accurately measured to minimise bias? Yes 5 (a) Have the authors identified all important confounding factors? Unclear (b) Have they taken account of the confounding factors in the design and/or analysis? Unclear 6 (a) Was the follow up of subjects complete enough? Yes (b) Was the follow up of subjects long enough? Yes <p>Overall risk of bias: Low</p> <p>Directness: directly applicable</p>

Full citation	Nakayama Atsuko, Morita Hiroyuki, Miyata Tetsuro, Ando Jiro, Fujita Hideo, Ohtsu Hiroshi, Akai Takafumi, Hoshina Katsuyuki, Nagayama Masatoshi, Takanashi Shuichiro, Sumiyoshi Tetsuya, and Nagai Ryoza (2012) Inverse association between the existence of coronary artery disease and progression of abdominal aortic aneurysm. <i>Atherosclerosis</i> 222(1), 278-83
Study details	<p>Study design: Retrospective cohort study</p> <p>Location(s): Japan</p> <p>Aim of the study: To investigate the coronary artery disease on the progression of AAA and the onset of major adverse cardiovascular events after elective surgical repair</p> <p>Study dates: January 2003 to March 2010</p> <p>Follow-up: minimum of 2 years</p> <p>Sources of funding: This research is supported by the Japan Society for the Promotion of Science</p>
Participants	<p>Sample size: 665</p> <p>Inclusion criteria: People who underwent elective surgical repair for AAA at a specialist centre. Surgical repair was offered to patients when aneurysms were greater than 5.0 cm in diameter.</p> <p>Exclusion criteria: Patients with AAAs that were diagnosed as being a direct consequence of a specific cause such as trauma, infection, inflammatory disease, or Marfan syndrome were excluded.</p>
Methods	<p>Data collection: The details of surgical management and patient clinical characteristics, before and after surgical repair, were obtained from medical records. Diameters of aneurysms were evaluated by computed tomography. Imaging intervals were not specified.</p> <p>Analysis: Multivariate logistic regression and Cox regression analysis, adjusting for age, sex, BMI, hypertension, dyslipidaemia, diabetes, smoking status, haemodialysis, coronary artery disease</p> <p>Baseline characteristics:</p> <ul style="list-style-type: none"> • Mean age: 73.3 years • Sex: 83% male • Mean aneurysm diameter: 53.5cm • Diabetes: 13% • Hypertension: 60% • Coronary heart disease: 46% • Peripheral arterial disease: 20%
Outcomes	<p>Outcome: Accelerated growth, defined as expansion rate greater than 5 mm per year</p> <p>Risk factors: Age; sex; BMI; hypertension; dyslipidaemia; diabetes; smoking status; haemodialysis; creatine levels (mg/dL); family history of AAA; family history of coronary artery disease; existence of preoperative coronary artery disease; ischaemic changes on ECG; presence of cerebral artery disease; presence of COPD; taking beta-blockers; taking ACE inhibitors; taking calcium-channel blockers; taking statins</p>

Full citation	Nakayama Atsuko, Morita Hiroyuki, Miyata Tetsuro, Ando Jiro, Fujita Hideo, Ohtsu Hiroshi, Akai Takafumi, Hoshina Katsuyuki, Nagayama Masatoshi, Takanashi Shuichiro, Sumiyoshi Tetsuya, and Nagai Ryoza (2012) Inverse association between the existence of coronary artery disease and progression of abdominal aortic aneurysm. <i>Atherosclerosis</i> 222(1), 278-83
Risk of bias assessment (using CASP tool)	<p>1. Did the study address a clearly focused issue? Yes</p> <p>2. Was the cohort recruited in an acceptable way? No – only patients who underwent elective surgical repair were included. Data from patients who had growing aneurysms that did not reach the threshold for surgical repair or patients who opted not to receive surgery were not included in the analysis. This may potentially lead to over- or under-estimations of effect sizes.</p> <p>3. Was the exposure accurately measured to minimise bias? Yes</p> <p>4. Was the outcome accurately measured to minimise bias? Yes</p> <p>5 (a) Have the authors identified all important confounding factors? Unclear (b) Have they taken account of the confounding factors in the design and/or analysis? No</p> <p>6 (a) Was the follow up of subjects complete enough? Yes (b) Was the follow up of subjects long enough? Yes</p> <p>Overall risk of bias: High Directness: directly applicable</p>

Full citation	Norman Paul, Spencer Carole A, Lawrence-Brown Michael M, and Jamrozik Konrad (2004) C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. <i>Circulation</i> 110(7), 862-6
Study details	<p>Study design: Retrospective cohort study</p> <p>Location(s): Australia</p> <p>Aim of the study: To assess the relationship between C-reactive protein (CRP) levels and small AAA expansion rates.</p> <p>Study dates: Not specified</p> <p>Follow-up: minimum of 1 year</p> <p>Sources of funding: Grants were received from the National Health and Medical Research Council (Australia), the National Heart Foundation (Australia), and Royal Perth Hospital Research Foundation</p>
Participants	<p>Sample size: 545</p> <p>Inclusion criteria: Men, between 65 and 83 years, with small AAAs (size range not specified) who were enrolled in a population-based screening study.</p> <p>Exclusion criteria: Not specified.</p> <p>Baseline characteristics:</p> <ul style="list-style-type: none"> • Mean age: not reported • Sex: 100% male • Mean aneurysm diameter: not reported • History of acute myocardial infarction: 28% • History of angina: 28% • History of stroke: 11% • History of diabetes: 10% • Hypertension: 46%
Methods	<p>Data collection: Data was used from databases of the Western Australia AAA screening study. In the screening study participants completed a question air on risk factors that included the Edinburgh Claudication questionnaire, had their height, weight, blood pressure, and circumference at the waist and hips recorded. C-reactive protein was measured by a high-sensitivity assay. Aneurysm diameters were determined using ultrasound imaging performed at 6 month intervals (for aneurysms ≥ 4.0 cm in diameter) or yearly intervals (for aneurysms 3.0 to 3.9 cm in diameter).</p> <p>Analysis: Multivariate logistic regression adjusting for age</p>
Outcomes	<p>Outcome: Aneurysm growth ≥ 3 mm (binary outcome)</p> <p>Risk factors: Initial aorta size; smoking status; C-reactive protein levels (mg/L)</p>
Risk of bias assessment	<ol style="list-style-type: none"> 1. Did the study address a clearly focused issue? Yes 2. Was the cohort recruited in an acceptable way? Yes

Full citation	Norman Paul, Spencer Carole A, Lawrence-Brown Michael M, and Jamrozik Konrad (2004) C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. Circulation 110(7), 862-6
(using CASP tool)	3. Was the exposure accurately measured to minimise bias? Yes 4. Was the outcome accurately measured to minimise bias? Yes 5 (a) Have the authors identified all important confounding factors? Unclear (b) Have they taken account of the confounding factors in the design and/or analysis? No 6 (a) Was the follow up of subjects complete enough? Yes (b) Was the follow up of subjects long enough? Yes Overall risk of bias: Moderate Directness: directly applicable

Full citation	Santilli S M, Littooy F N, Cambria R A, Rapp J H, Tretinyak A S, d'Audiffret A C, Kuskowski M A, Roethle S T, Tomczak C M, and Krupski W C (2002) Expansion rates and outcomes for the 3.0-cm to the 3.9-cm infrarenal abdominal aortic aneurysm. Journal of vascular surgery : official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, and North American Chapter 35(4), 666-671
Study details	<p>Study design: Retrospective cohort study</p> <p>Location(s): USA</p> <p>Aim of the study: To determine expansion rates and outcomes of people with AAA</p> <p>Study dates: December 1992 to November 2000</p> <p>Follow-up: mean of 3.89 years</p> <p>Sources of funding: Not reported</p>
Participants	<p>Sample size: 790</p> <p>Inclusion criteria: People with AAAs between 3.0 and 3.9 cm in diameter who were screened for the ADAM randomised controlled trial (including those patients who were not randomised into the trial). All participants had at least 1 follow-up aneurysm diameter measurement taken at least 90 days following initial screening.</p> <p>Exclusion criteria: Not specified</p> <p>Baseline characteristics:</p> <p>Mean age: 69.1 years</p> <p>Sex: 100% male</p> <p>Mean aneurysm diameter: 3.3 cm</p> <p>Comorbidities: not reported</p>
Methods	<p>Data collection: Before the initial ultrasound screening, all patients completed a brief questionnaire to obtain demographic and risk factor information. The patients were asked whether they had ever been told by a physician that they had the risk factors in question. Aneurysm diameters (antero-posterior and lateral planes) were obtained using ultrasound imaging. Imaging intervals were not specified.</p> <p>Analysis: Multivariate logistic regression. No further details were provided</p>
Outcomes	<p>Outcome: aneurysm growth (ordinal outcomes) and aneurysm rupture</p> <p>Risk factors: initial infrarenal aortic diameter; age; family history of AAA; smoking status; cardiovascular disease (history of angina, stroke, myocardial infarction, or coronary artery bypass grafting); claudication; diabetes; hypertension (previous diagnosis or current medication); or hypercholesterolemia (previous diagnosis or current medication)</p>
Risk of bias assessment (using CASP tool)	<ol style="list-style-type: none"> 1. Did the study address a clearly focused issue? Yes 2. Was the cohort recruited in an acceptable way? Yes 3. Was the exposure accurately measured to minimise bias? No - Before the initial ultrasound screening, all patients completed a brief questionnaire to obtain demographic and risk factor information. The patients were asked whether they had ever been told by a physician that they had the risk factors in question.

Full citation	Santilli S M, Littooy F N, Cambria R A, Rapp J H, Tretinyak A S, d'Audiffret A C, Kuskowski M A, Roethle S T, Tomczak C M, and Krupski W C (2002) Expansion rates and outcomes for the 3.0-cm to the 3.9-cm infrarenal abdominal aortic aneurysm. Journal of vascular surgery : official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, and North American Chapter 35(4), 666-671
	4. Was the outcome accurately measured to minimise bias? Yes 5 (a) Have the authors identified all important confounding factors? Unclear (b) Have they taken account of the confounding factors in the design and/or analysis? No 6 (a) Was the follow up of subjects complete enough? Yes (b) Was the follow up of subjects long enough? Yes Overall risk of bias: Moderate Directness: directly applicable

Full citation	Thompson S G, Brown L C, Sweeting M J, Bown M J, Kim L G, Glover M J, Buxton M J, and Powell J T (2013) Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness. Health technology assessment (Winchester, and England) 17(41), 1-118
Study details	<p>Study design: Individual patient data meta-analysis using data from randomised controlled trials and disease registries</p> <p>Location(s): UK</p> <p>Aim of the study: To inform the evidence base for small AAA surveillance strategies.</p> <p>Study dates: literature searched up to September 2012</p> <p>Follow-up: mean of 4.0 years</p> <p>Sources of funding: Funding was received from the National Institute for Health Research Health Technology Assessment programme.</p>
Participants	<p>Sample size: 18 studies, including 15,475</p> <p>Inclusion criteria: Studies including more than 100 patients with AAAs between 3.0 and 5.5 cm in diameter.</p> <p>Exclusion criteria: Studies in which patient data were duplicated, non-human studies, editorials, letters, case reports, studies using patients previously treated by AAA surgery or aneurysms of other arteries, and studies reporting on patients with Marfan syndrome were excluded</p> <p>Baseline characteristics: baseline characteristics of the pooled study cohort were not reported. Instead, baseline characteristics of patients in each individual study were reported separately.</p>
Methods	<p>Data collection: Data sets for were identified through a systematic literature search. Upon identification of relevant studies requests for individual patient data were sent to principal investigators of each study. Data requested included age, sex, sequential aneurysm diameters, ethnicity, smoking history, BMI, presence of diabetes, dates of aneurysm repair, aneurysm rupture or death. A pragmatic definition of aneurysm rupture was used, based on locally used definitions and reporting. Aneurysm diameters were measured using ultrasound imaging or computed tomography. For each individual, the baseline measurement was defined as the first measurement recorded between 3.0 and 5.4 cm. Any measurements taken before the aneurysm reached 3.0 cm were not considered in the analysis. All data following baseline measurements were used until the point that aneurysms exceeded 5.5 cm in diameter, the patient received underwent elective surgical repair, the patient died of non-related causes or the date of administrative censoring of the data set.</p> <p>Aneurysm growth analysis: Each predictor was considered in a quadratic random-effects model. To allow studies that recorded both ultrasound imagine and computed-tomography to be included, a dummy variable was added to distinguish between the 2 imaging modalities. Multivariate analysis was performed adjusting for age, calendar year, sex, smoking, diabetes, mean arterial blood pressure/pulse pressure, history of cardiovascular disease, and additionally any recorded use of angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, calcium-channel blockers, statins or lipid-lowering medicines, and antiplatelet use. Studies that did not collect all these covariates were adjusted for as many covariates in the list as possible.</p> <p>Aneurysm rupture analysis: Cox regression analysis was performed, adjusting for aneurysm diameter (entered as a time-varying covariate)</p>
Outcomes	<p>Outcome: Aneurysm growth and aneurysm rupture</p> <p>Risk factors: Age; sex; smoking status; BMI; diabetes; mean arterial blood pressure (per 10 mmHg); pulse pressure (per 10 mmHg); history of cardiovascular disease.</p>

Full citation	Thompson S G, Brown L C, Sweeting M J, Bown M J, Kim L G, Glover M J, Buxton M J, and Powell J T (2013) Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness. Health technology assessment (Winchester, and England) 17(41), 1-118
Appraisal of study quality	<ol style="list-style-type: none"> 1. Did the review follow a protocol? Yes 2. Did inclusion criteria allow the right studies to be identified? Yes 3. Were restrictions based on study characteristics and information sources appropriate? Yes 4. Did the search include a range of databases and other sources for published and unpublished reports? Yes 5. Were the terms and structure of the search strategy suitable? Yes 6. Were efforts made to minimise errors in selection of studies? Yes 7. Did authors provide a description of how IPD were requested, collected and managed? Yes 8. Did authors describe which aspects of IPD were subject to data checking and how this was done? Yes 9. Were efforts made to minimise errors in data collection? Yes 10. Were sufficient study characteristics reported? Yes 11. Were all relevant study results included? Yes 12. Was the integrity of IPD assessed? Yes 13. Did the authors describe methods used to assess risk of bias in the individual studies and whether this was applied separately for each outcome? Unclear – Authors do not report whether a risk of bias tool was used to assess the quality of identified studies 14. Was heterogeneity minimal or addressed in the synthesis? Heterogeneity varied according to risk factor assessed (up to 98%). Not all patient demographics data was available from included studies. Most studies used ultrasound imaging to measure the diameters of aneurysms; however, a few of the studies used computed-tomography. Some studies measured external (outer-to-outer) wall diameters, whereas others (n=3) measured internal diameters. Study-specific thresholds for surgical intervention varied from 4.5 cm up to 6.0 cm 15. Were the findings robust? Unclear – no regression or sensitivity analyses were performed <p>Overall risk of bias: Moderate Directness: directly applicable</p>

Appendix E – GRADE tables

Risk factors associated with aneurysm growth

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
Age									
Over 65 vs. under 65	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2}	N/A	Not serious	Serious ⁴	665	HR ^a 0.84 (0.38, 1.85)	Very low
Age (continuous)	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Serious ⁴	652	OR ^a 1.10 (0.93, 1.30)	Moderate
Sex									
Males vs. females	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2}	N/A	Not serious	Serious ⁴	665	HR ^a 1.88 (0.89, 3.96)	Very low
Males vs. females	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Serious ⁴	652	OR ^a 0.77 (0.376, 1.56)	Moderate
Smoking status									
Ex-smoker vs. lifelong smoker	1 Norman (2004)	Retrospective cohort	Serious ¹	N/A	Not serious	Serious ⁴	545	OR ^a 0.9 (0.4, 1.8)	Low
Current smoker vs. lifelong smoker	1 Norman (2004)	Retrospective cohort	Serious ¹	N/A	Not serious	Serious ⁴	545	OR ^a 1.8 (0.8, 4.1)	Low
Ex-smoker vs. non-smoker	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2, 3}	N/A	Not serious	Serious ⁴	665	HR ^a 1.1 (0.7, 1.7) *estimated from a graph	Very low

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
Current smoker vs. non-smoker	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2,3}	N/A	Not serious	Serious ⁴	665	HR ^a 1.77 (0.97, 3.22)	Very low
Ex-smoker vs. non smoker	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Serious ⁴	652	OR ^a 0.75 (0.47, 1.20)	Moderate

a. As multivariate analyses were performed, hazard and odds ratios were reported adjusting for confounders or other factors.

1. Retrospective cohort in which confounding was not adequately assessed, downgrade 1 level.

2. Only patients who underwent elective surgical repair were included. Data from patients who had growing aneurysms that did not reach the threshold for surgical repair or patients who opted not to receive surgery were not included, downgrade 1 level

3. Results were reported graphically, downgrade 1 level.

4. 95% CI crosses the line of no effect, downgrade 1 level.

5. 95% CI not reported, downgrade 2 levels.

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
BMI									
BMI >25 vs. BMI <25	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2}	N/A	Not serious	Serious ⁴	665	HR ^a 0.82 (0.45, 1.50)	Very low
Family history of AAA									
History vs. no history	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2,3}	N/A	Not serious	Serious ⁴	665	HR ^a 1.2 (0.5, 2.9) *estimated from a graph	Very low
Coronary artery disease									
Presence vs. absence	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Not serious	652	OR ^a 0.67 (0.46, 0.97)	High
Presence vs. absence	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2}	N/A	Not serious	Not serious	665	HR ^a 0.55 (0.32, 0.94)	Low
Family history vs. no history	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2,3}	N/A	Not serious	Serious ⁴	665	HR ^a 0.8 (0.3, 1.75) *estimated from a graph	Very low
Peripheral artery disease									
Presence vs. absence	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Serious ⁴	652	OR ^a 0.96 (0.62, 1.48)	Moderate

a. As multivariate analyses were performed, hazard and odds ratios were reported adjusting for confounders or other factors.

1. Retrospective cohort in which confounding was not adequately assessed, downgrade 1 level.

2. Only patients who underwent elective surgical repair were included. Data from patients who had growing aneurysms that did not reach the threshold for surgical repair or patients who opted not to receive surgery were not included, downgrade 1 level

3. Results were reported graphically, downgrade 1 level.

4. 95% CI crosses the line of no effect, downgrade 1 level.

5. 95% CI not reported, downgrade 2 levels.

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
COPD									
Presence vs. absence	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2,3}	N/A	Not serious	Serious ⁴	665	HR ^a 1.4 (0.75, 2.3) *estimated from a graph	Very low
Hypertension									
Presence vs. absence	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2}	N/A	Not serious	Serious ⁴	665	HR ^a 0.97 (0.52, 1.81)	Very low
Presence vs. absence	1 Santilli (2002)	Retrospective cohort	Serious ¹	N/A	Not serious	Very serious ⁵	790	OR ^a 2.5 *Significant: 95% CI not reported	Very low
Presence vs. absence	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Serious ⁴	652	OR ^a 0.92 (0.64, 1.31)	Moderate
Dyslipidaemia									
Presence vs. absence	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2}	N/A	Not serious	Serious ⁴	665	HR ^a 1.02 (0.58, 1.80)	Very low

a. As multivariate analyses were performed, hazard and odds ratios were reported adjusting for confounders or other factors.

1. Retrospective cohort in which confounding was not adequately assessed, downgrade 1 level.

2. Only patients who underwent elective surgical repair were included. Data from patients who had growing aneurysms that did not reach the threshold for surgical repair or patients who opted not to receive surgery were not included, downgrade 1 level

3. Results were reported graphically, downgrade 1 level.

4. 95% CI crosses the line of no effect, downgrade 1 level.

5. 95% CI not reported, downgrade 2 levels.

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
Diabetes									
Presence vs. absence	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2}	N/A	Not serious	Serious ⁴	665	HR ^a 0.88 (0.49, 1.58)	Very low
Presence vs. absence	1 Santilli (2002)	Retrospective cohort	Serious ¹	N/A	Not serious	Very serious ⁵	790	OR ^a 0.60 *Significant: 95% CI not reported	Very low
Presence vs. absence	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Not serious	652	OR ^a 0.37 (0.22, 0.62)	High
Claudication									
Presence vs. absence	1 Santilli (2002)	Retrospective cohort	Serious ¹	N/A	Not serious	Very serious ⁵	790	OR ^a 0.35 *Significant: 95% CI not reported	Very low
Haemodialysis									
Presence vs. absence	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2}	N/A	Not serious	Serious ⁴	665	HR ^a 1.85 (0.48, 7.2)	Very low
Cerebral artery disease									
Presence vs. absence	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2, 3}	N/A	Not serious	Serious ⁴	665	HR ^a 1.7 (0.85, 3.2) *estimated from a graph	Very low
<p>a. As multivariate analyses were performed, hazard and odds ratios were reported adjusting for confounders or other factors.</p> <p>1. Retrospective cohort in which confounding was not adequately assessed, downgrade 1 level.</p> <p>2. Only patients who underwent elective surgical repair were included. Data from patients who had growing aneurysms that did not reach the threshold for surgical repair or patients who opted not to receive surgery were not included, downgrade 1 level.</p> <p>3. Results were reported graphically, downgrade 1 level.</p> <p>4. 95% CI crosses the line of no effect, downgrade 1 level.</p> <p>5. 95% CI not reported, downgrade 2 levels.</p>									

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
Ischaemic changes on ECG									
Changes vs. no changes	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1,2,3}	N/A	Not serious	Serious ⁴	665	HR ^a 0.45 (0.1, 1.5) *estimated from a graph	Very low
Initial AAA diameter									
4.0-5.4 cm vs. 3.0-3.9 cm	1 Norman (2004)	Retrospective cohort	Serious ¹	N/A	Not serious	Not serious	545	OR ^a 7.2 (4.3, 12.2)	Moderate
Per 4.3 mm (continuous)	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Not serious	652	OR ^a 1.78 (1.49, 2.14)	High
C-reactive protein levels (mg/L)									
1.2-2.1 vs. <1.2	1 Norman (2004)	Retrospective cohort	Serious ¹	N/A	Not serious	Serious ⁴	545	OR ^a 1.3 (0.6, 2.9)	Low
2.2-3.5 vs. <1.2	1 Norman (2004)	Retrospective cohort	Serious ¹	N/A	Not serious	Serious ⁴	545	OR ^a 0.9 (0.4, 2.2)	Low
3.6-6.2 vs. <1.2	1 Norman (2004)	Retrospective cohort	Serious ¹	N/A	Not serious	Serious ⁴	545	OR ^a 1.0 (0.4, 2.4)	Low
≥ 6.3 vs. <1.2	1 Norman (2004)	Retrospective cohort	Serious ¹	N/A	Not serious	Serious ⁴	545	OR ^a 1.9 (0.9, 4.1)	Low
Creatinine levels (mg/L)									
>1.5 vs <1.5	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1,2,3}	N/A	Not serious	Serious ⁴	665	HR ^a 1.65 (0.7, 3.7) *estimated from a graph	Very low

a. As multivariate analyses were performed, hazard and odds ratios were reported adjusting for confounders or other factors.

1. Retrospective cohort in which confounding was not adequately assessed, downgrade 1 level.

2. Only patients who underwent elective surgical repair were included. Data from patients who had growing aneurysms that did not reach the threshold for surgical repair or patients who opted not to receive surgery were not included, downgrade 1 level

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
3. Results were reported graphically, downgrade 1 level. 4. 95% CI crosses the line of no effect, downgrade 1 level. 5. 95% CI not reported, downgrade 2 levels.									

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
Aspirin									
Taking vs. not taking	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Serious ⁴	652	OR ^a 1.10 (0.78, 1.56)	Moderate
Beta-blockers									
Taking vs. not taking	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2,3}	N/A	Not serious	Serious ⁴	665	HR ^a 1.9 (0.5, 1.4) *estimated from a graph	Very low
Taking vs. not taking	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Serious ⁴	652	OR ^a 1.13 (0.76, 1.67)	Moderate
ACE inhibitors									
Taking vs. not taking	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2,3}	N/A	Not serious	Serious ⁴	665	HR ^a 0.8 (0.4, 1.7) *estimated from a graph	Very low
Taking vs. not taking	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Serious ⁴	652	OR ^a 0.91 (0.64, 1.31)	Moderate
Angiotensin receptor blockers									
Taking vs. not taking	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2,3}	N/A	Not serious	Serious ⁴	665	HR ^a 0.75 (0.45, 1.15) *estimated from a graph	Very low
Calcium-channel blockers									

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
Taking vs. not taking	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2,3}	N/A	Not serious	Serious ⁴	665	HR ^a 1.0 (0.6, 1.4) *estimated from a graph	Very low
Statins									
Taking vs. not taking	1 Nakayama (2012)	Retrospective cohort	Very serious ^{1, 2,3}	N/A	Not serious	Not serious	665	HR ^a 0.65 (0.3, 0.9) *estimated from a graph	Very low
Taking vs. not taking	1 Ferguson (2010)	Prospective cohort	Not serious	N/A	Not serious	Serious ⁴	652	OR ^a 1.23 (0.86, 1.76)	Moderate

a. As multivariate analyses were performed, hazard and odds ratios were reported adjusting for confounders or other factors.

1. Retrospective cohort in which confounding was not adequately assessed, downgrade 1 level.

2. Only patients who underwent elective surgical repair were included. Data from patients who had growing aneurysms that did not reach the threshold for surgical repair or patients who opted not to receive surgery were not included, downgrade 1 level

3. Results were reported graphically, downgrade 1 level.

4. 95% CI crosses the line of no effect, downgrade 1 level.

5. 95% CI not reported, downgrade 2 levels.

Risk factors associated with aneurysm rupture

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
Age									
Years per tertile group (59-66 vs. 67-71 vs. 72-77)	1 Brown (1999)	Prospective cohort	Not serious	N/A	Not serious	Serious ¹	2,256	HR ^a 1.03 (0.98, 1.08)	Moderate
Per year (continuous)	1 Thompson (2013)	IPD meta-analysis	Serious ²	Serious ³	Not serious	Not serious	15,475	HR ^a 1.04 (1.01, 1.07)	Low
Sex									
Females vs males	1 Brown (1999)	Prospective cohort	Not serious	N/A	Not serious	Not serious	2,256	HR ^a 3.0 (1.99, 4.53)	High
Females vs. males	1 Thompson (2013)	IPD meta-analysis	Serious ²	Serious ³	Not serious	Not serious	15,475	HR ^a 3.76 (2.58, 5.47)	Low
Smoking status									
Ex-smokers vs. current smoker	1 Brown (1999)	Prospective cohort	Not serious	N/A	Not serious	Not serious	2,242	HR ^a 0.59 (0.39, 0.89)	High
Never-smokers vs. current smoker	1 Brown (1999)	Prospective cohort	Not serious	N/A	Not serious	Serious ¹	2,242	HR ^a 0.65 (0.27, 1.53)	Moderate
Current smokers vs. ex/never smokers	1 Thompson (2013)	IPD meta-analysis	Serious ²	Serious ³	Not serious	Not serious	15,475	HR ^a 2.02 (1.33, 1.53)	Low

a. As multivariate analyses were performed, hazard and odds ratios were reported adjusting for confounders or other factors.

1. 95% CI crosses the line of no effect, downgrade 1 level.

2. Authors did not use a risk of bias assessment tool to assess the quality of included studies, downgrade 1 level.

3. Inconsistency between included studies: Most studies used ultrasound imaging to measure the diameters of aneurysms; however, a few of the studies used computed-tomography. Some studies measured external (outer-to-outer) wall diameters, whereas others measured internal diameters. Study-specific thresholds for surgical intervention varied from 4.5 cm to 6.0 cm.

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
BMI									
BMI by tertile group (15-23.3 vs. 23.4-26.3 vs. 26.4-42.1)	1 Brown (1999)	Prospective cohort	Not serious	N/A	Not serious	Serious ¹	2,242	HR ^a 0.99 (0.94, 1.04) per kg/m ²	Moderate
BMI (continuous)	1 Thompson (2013)	IPD meta-analysis	Serious ²	Serious ³	Not serious	Not serious	15,475	HR ^a 0.93 (0.88, 0.99) per kg/m ²	Low
Diabetes									
Presence vs. absence	1 Thompson (2013)	IPD meta-analysis	Serious ²	Serious ³	Not serious	Serious ¹	15,475	HR ^a 1.27 (0.45, 3.54)	Very low
Arterial blood pressure									
Mean blood pressure by tertile group (57-102 vs. 103-116 vs. 117-193)	1 Brown (1999)	Prospective cohort	Not serious	N/A	Not serious	Not serious	2,222	HR ^a 1.02 (1.00, 1.03) per mmHg	High
Mean blood pressure (continuous)	1 Thompson (1999)	IPD meta-analysis	Serious ²	Serious ³	Not serious	Not serious	15,475	HR ^a 1.32 (1.11, 1.56) per 10 mmHg	Low
Pulse pressure									
Pulse pressure (continuous)	1 Thompson (2013)	IPD meta-analysis	Serious ²	Serious ³	Not serious	Not serious	15,475	HR ^a 1.11 (1.02, 1.22) per 10 mmHg	Low

a. As multivariate analyses were performed, hazard and odds ratios were reported adjusting for confounders or other factors.

1. 95% CI crosses the line of no effect, downgrade 1 level.

2. No risk of bias tool was used to assess the quality of included studies, downgrade 1 level.

3. Inconsistency between included studies: Most studies used ultrasound imaging to measure the diameters of aneurysms; however, a few of the studies used computed-tomography. Some studies measured external (outer-to-outer) wall diameters, whereas others measured internal diameters. Study-specific thresholds for surgical intervention varied from 4.5 cm to 6.0 cm.

Predictor	No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	No. of participants	Effect size (95% CI)	Quality
Ankle-brachial pressure index measurement (ABPI)									
Mean ABPI by tertile group (0.02-0.86 vs. 0.87-1.03 vs. 1.04-1.90)	1 Brown (1999)	Prospective cohort	Not serious	N/A	Not serious	Serious ¹	2,146	HR ^a 0.93 (0.34, 2.58) per unit	Moderate
Cholesterol levels									
mmoL by tertile group (1.6-5.6 vs. 5.7-6.6 vs. 6.7-16.9)	1 Brown (1999)	Prospective cohort	Not serious	N/A	Not serious	Serious ¹	2,107	HR ^a 0.92 (0.78, 1.08) per mmol/L	Moderate
History of cardiovascular disease									
History vs. no history	1 Thomps on (2013)	IPD meta-analysis	Serious ²	Serious ³	Not serious	Serious ¹	15,475	HR ^a 1.32 (0.77, 2.27)	Very low
Initial AAA diameter									
Diameter ranges (3.0-3.9 vs. 4.0-5.5 vs. 5.6-9.7)	1 Brown (1999)	Prospective cohort	Not serious	N/A	Not serious	Not serious	2,257	HR ^a 2.97 (2.49, 3.48)	High


a. As multivariate analyses were performed, hazard and odds ratios were reported adjusting for confounders or other factors.

1. 95% CI crosses the line of no effect, downgrade 1 level.

2. No risk of bias tool was used to assess the quality of included studies, downgrade 1 level.

3. Inconsistency between included studies: Most studies used ultrasound imaging to measure the diameters of aneurysms; however, a few of the studies used computed-tomography. Some studies measured external (outer-to-outer) wall diameters, whereas others measured internal diameters. Study-specific thresholds for surgical intervention varied from 4.5 cm to 6.0 cm.

Appendix F – Economic evidence study selection



Appendix G – Excluded studies

Clinical studies

No.	Study	Reason for exclusion
1	Behr-Rasmussen C, Grondal N, Bramsen M B, Thomsen M D, and Lindholt J S (2014) Mural thrombus and the progression of abdominal aortic aneurysms: A large population-based prospective cohort study. <i>European Journal of Vascular and Endovascular Surgery</i> 48(3), 301-307	Although study abstract indicates that 615 patients had AAA, only 416 were included in the analysis.
2	Bhak Rachel H, Winger Michael, Johnson Gary R, Lederle Frank A, Messina Louis M, Ballard David J, Wilson Samuel E, Aneurysm Detection, Management Study, and Group (2015) Factors associated with small abdominal aortic aneurysm expansion rate. <i>JAMA surgery</i> 150(1), 44-50	No data of interest: aneurysm growth rates were calculated by linear regression analysis. This is a different outcome to that specified in the review protocol: “radiological diagnosis of abdominal aortic aneurysm expansion; single test within a study”
3	Brady Anthony R, Thompson Simon G, Fowkes F Gerald R, Greenhalgh Roger M, Powell Janet T, and Participants U K. Small Aneurysm Trial (2004) Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. <i>Circulation</i> 110(1), 16-21	No data of interest: aneurysm growth rates were calculated by linear regression analysis. This is a different outcome to that specified in the review protocol: “radiological diagnosis of abdominal aortic aneurysm expansion; single test within a study”
4	Brown M J, Sweeting M J, Brown L C, Powell J T, and Thompson S G (2013) Surveillance intervals for small abdominal aortic aneurysms: A meta-analysis. <i>JAMA - Journal of the American Medical Association</i> 309(8), 806-813	This meta-analysis of individual patient data, estimates aneurysm growth rates (mm/year) and rupture rates (per 1000 patient years) according to aneurysm diameter at diagnosis. Although partially applicable, multivariate analysis was not performed to assess risk factors for aneurysm growth or rupture.
5	Brown Peter M, Sobolev Boris, and Zelt David T (2003) Selective management of abdominal aortic aneurysms smaller than 5.0 cm in a prospective sizing program with gender-specific analysis. <i>Journal of vascular surgery</i> 38(4), 762-5	Multivariate analysis was not performed to assess risk factors associated with aneurysm expansion or rupture.
6	Brunner-Ziegler Sophie, Hammer Alexandra, Seidinger Daniela, Willfort-Ehringer Andrea, Koppensteiner Renate, and Steiner Sabine (2015) The role of intraluminal thrombus formation for expansion of abdominal aortic aneurysms. <i>Wiener klinische Wochenschrift</i> 127(13-14), 549-54	The study had a sample size of less than 500 participants (n=116).
7	Chang J B, Stein T A, Liu J P, and Dunn M E (1997) Risk factors associated with rapid growth of small abdominal aortic aneurysms. <i>Surgery</i> 121(2), 117-122	The population of interest for this review question is “people with a confirmed AAA greater than 3.0 cm in diameter. In this study 50.5% (260/514) of participants had AAAs less than 3.0 cm in diameter.

No.	Study	Reason for exclusion
8	Cronin Oliver, Walker Philip J, and Golledge Jonathan (2013) The association of obesity with abdominal aortic aneurysm presence and growth. <i>Atherosclerosis</i> 226(2), 321-7	Systematic review including studies which employed various study designs (including case-controls, screening programs and cohort studies). Individual studies were assessed to determine if they met inclusion criteria for this review question.
9	De Rango , P , Farchioni L, Fiorucci B, and Lenti M (2014) Diabetes and abdominal aortic aneurysms. <i>European Journal of Vascular and Endovascular Surgery</i> 47(3), 243-261	Systematic review assessing the association between diabetes and AAAs. Population-based screening programmes, case-controls and prospective observational studies were included. Individual studies were assessed to determine if they met inclusion criteria for this review question.
10	Deeg Mark A, Meijer C Arnoud, Chan Lai Shan, Shen Lei, and Lindeman Jan H. N (2016) Prognostic and predictive biomarkers of abdominal aortic aneurysm growth rate. <i>Current medical research and opinion</i> 32(3), 509-17	Sample size less than 500 participants.
11	Harris P L, Vallabhaneni S R, Desgranges P, Becquemin J P, Van Marrewijk , C , and Laheij R J. F (2000) Incidence and risk factors of late rupture, conversion, and death after endovascular repair of infrarenal aortic aneurysms: The EUROSTAR experience. <i>Journal of Vascular Surgery</i> 32(4), 739-749	Authors reported that multivariate analysis was not possible because the number of observed aneurysm ruptures was too small.
12	Hatakeyama T, Shigematsu H, and Muto T (2001) Risk factors for rupture of abdominal aortic aneurysm based on three-dimensional study. <i>Journal of vascular surgery</i> 33(3), 453-61	No sample size data were available in the study abstract. Assessment of the full manuscript reveals that 39 patients with an atherosclerotic AAA met the inclusion criteria for this study.
13	Hendy K, Gunnarson R, and Golledge J (2014) Growth rates of small abdominal aortic aneurysms assessed by computerised tomography - A systematic literature review. <i>Atherosclerosis</i> 235(1), 182-188	Systematic review including prospective and retrospective observational studies. All included studies had sample sizes of less than 200 participants
14	Jalalzadeh H, Indrakusuma R, Planken R N, Legemate D A, Koelemay M J. W, and Balm R (2016) Inflammation as a Predictor of Abdominal Aortic Aneurysm Growth and Rupture: A Systematic Review of Imaging Biomarkers. <i>European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</i> 52(3), 333-42	Systematic review of cohort studies which were out of scope of this review question. Studies assessed the diagnostic utility of inflammatory imaging biomarkers using advanced imaging techniques. Furthermore, none of the studies had sample sizes more than 500 participants.
15	Johnsen S H, Forsdahl S H, Solberg S, Singh K, and Jacobsen B K (2013) Carotid atherosclerosis and relation to growth of infrarenal aortic diameter and follow-up diameter: The tromso study.	Only 132 people with AAAs were included in the multivariate logistic regression model

No.	Study	Reason for exclusion
	European Journal of Vascular and Endovascular Surgery 45(2), 135-140	
16	Kleinstreuer Clement, and Li Zhonghua (2006) Analysis and computer program for rupture-risk prediction of abdominal aortic aneurysms. Biomedical engineering online 5, 19	Not primary research. This study outlines how a computer program can be used to develop an AAA risk assessment tool using data from previously published studies (effectively secondary data analysis).
17	Lederle Frank A, Wilson Samuel E, Johnson Gary R, Reinke Donovan B, Littooy Fred N, Acher Charles W, Ballard David J, Messina Louis M, Gordon Ian L, Chute Edmund P, Krupski William C, Busuttill Steven J, Barone Gary W, Sparks Steven, Graham Linda M, Rapp Joseph H, Makaroun Michel S, Moneta Gregory L, Cambria Robert A, Makhoul Raymond G, Eton Darwin, Ansel Howard J, Freischlag Julie A, Bandyk Dennis, Aneurysm Detection, Management Veterans Affairs Cooperative Study, and Group (2002) Immediate repair compared with surveillance of small abdominal aortic aneurysms. The New England journal of medicine 346(19), 1437-44	Multivariate analysis was not performed to assess risk factors associated with aneurysm expansion or rupture.
18	Lederle F A, Noorbaloochi S, Nugent S, Taylor B C, Grill J P, Kohler T R, and Cole L (2015) Multicentre study of abdominal aortic aneurysm measurement and enlargement. The British journal of surgery 102(12), 1480-7	Case-control: patients with AAA growth were identified via medical records and imaging reports, and were subsequently assessed for risk factors.
19	Louridas G, Reilly K, and Perry M O (1990) The role of the aortic aneurysm diameter aortic diameter ratio in predicting the risk of rupture. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 78(11), 642-3	The study had a sample size of less than 500 participants (n=130).
20	Matthews E O, Rowbotham S E, Moxon J V, Jones R E, Vega de Ceniga, M, and Golledge J (2017) Meta-analysis of the association between peripheral artery disease and growth of abdominal aortic aneurysms. The British journal of surgery 104(13), 1765-1774	Systematic review which included studies that employed multiple study designs. Individual studies were assessed to establish if they met criteria for inclusion in this NICE review.
21	McCarthy R J, Shaw E, Whyman M R, Earnshaw J J, Poskitt K R, and Heather B P (2003) Recommendations for screening intervals for small aortic aneurysms. The British journal of surgery 90(7), 821-6	Multivariate analysis was not performed to assess risk factors associated with aneurysm expansion or rupture.
22	Mofidi R, Goldie V J, Kelman J, Dawson A R. W, Murie J A, and Chalmers R T. A (2007) Influence of sex on expansion	Multivariate analysis was not performed to assess risk factors associated with aneurysm expansion or rupture.

No.	Study	Reason for exclusion
	rate of abdominal aortic aneurysms. The British journal of surgery 94(3), 310-4	
23	Newby D (2017) Aortic Wall Inflammation Predicts Abdominal Aortic Aneurysm Expansion, Rupture and Need for Surgical Repair. Circulation (no pagination),	The study had a sample size of less than 500 participants (n=342).
24	Parkinson Fran, Ferguson Stuart, Lewis Peter, Williams Ian M, Twine Christopher P, South East Wales Vascular, and Network (2015) Rupture rates of untreated large abdominal aortic aneurysms in patients unfit for elective repair. Journal of vascular surgery 61(6), 1606-12	Systematic review including cohort studies and RCTs; none of which had sample sizes of 500 participants, or larger.
25	Powell Janet T, Brown Louise C, Greenhalgh Roger M, and Thompson Simon G (2008) The rupture rate of large abdominal aortic aneurysms: is this modified by anatomical suitability for endovascular repair?. Annals of surgery 247(1), 173-9	Systematic review including studies which employed prospective and retrospective study designs; none of which had sample sizes of 500 participants, or larger.
26	Powell J T, Gotensparre S M, Sweeting M J, Brown L C, Fowkes F G. R, and Thompson S G (2011) Rupture rates of small abdominal aortic aneurysms: A systematic review of the literature. European Journal of Vascular and Endovascular Surgery 41(1), 2-10	Systematic review including studies which employed prospective and retrospective study designs. Individual studies were assessed to determine whether they met inclusion criteria for this review question.
27	Scott R Alan P, Kim Lois G, Ashton Hilary A, Multi-centre Aneurysm Screening Study, and Group (2005) Assessment of the criteria for elective surgery in screen-detected abdominal aortic aneurysms. Journal of medical screening 12(3), 150-4	Multivariate analysis was not performed to assess risk factors associated with aneurysm expansion or rupture. Instead, multivariate regression was performed to investigate the effect of aortic diameter and patient age on the decision to return a patient for surveillance (versus elective surgery).
28	Sweeting M J, Thompson S G, Brown L C, Powell J T, and collaborators Rescan (2012) Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. The British journal of surgery 99(5), 655-65	Duplication of data from the Health Technology Assessment by Thompson et al. (2013) which has been included in this review.
29	Takagi Hisato, Umemoto Takuya, and Group Alice (2016) Coronary artery disease and abdominal aortic aneurysm growth. Vascular medicine (London, and England) 21(3), 199-208	Systematic review which included studies that employed multiple study designs. Individual studies were assessed to establish if they met criteria for inclusion in this NICE review.
30	Takagi Hisato, Umemoto Takuya, and Group Alice (2016) Association of peripheral artery disease with abdominal aortic aneurysm growth. Journal of vascular surgery 64(2), 506-513	Systematic review which included studies that employed multiple study designs. Individual studies were assessed to establish if they met criteria for inclusion in this NICE review.

No.	Study	Reason for exclusion
31	Takagi Hisato, Umemoto Takuya, and Group Alice (2016) Negative association of diabetes with rupture of abdominal aortic aneurysm. <i>Diabetes & vascular disease research</i> 13(5), 341-7	Systematic review which included studies that employed multiple study designs. Individual studies were assessed to establish if they met criteria for inclusion in this NICE review.
32	Takagi H, and Umemoto T (2017) Association of chronic obstructive pulmonary, coronary artery, or peripheral artery disease with abdominal aortic aneurysm rupture. <i>International Angiology</i> 36(4), 322-331	Systematic review of case-controls.
33	Takagi Hisato, and Umemoto Takuya (2016) The association between body mass index and abdominal aortic aneurysm growth: a systematic review. <i>VASA. Zeitschrift fur Gefasskrankheiten</i> 45(2), 119-24	Systematic review including studies which employed various study designs (including case-controls, screening programs and cohort studies). Individual studies were assessed to determine if they met inclusion criteria for this review question.
34	The Propranolol Aneurysm Trial Investigators (2002) Propranolol for small abdominal aortic aneurysms: results of a randomized trial. <i>Journal of vascular surgery : official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, and North American Chapter</i> 35(1), 72-79	Study assessed whether propranolol reduced aneurysm growth rates.
35	Thompson S G, Ashton H A, Gao L, Buxton M J, Scott R A. P, Multicentre Aneurysm Screening Study, and Group (2012) Final follow-up of the Multicentre Aneurysm Screening Study (MASS) randomized trial of abdominal aortic aneurysm screening. <i>The British journal of surgery</i> 99(12), 1649-56	Study did not assess risk factors associated with aneurysm rupture or growth. Instead, unadjusted Cox regression was used to compare deaths related to abdominal aortic aneurysm and all-cause mortality between individuals in two randomised groups.
36	Thompson S G, Ashton H A, Gao L, Scott R A. P, Multicentre Aneurysm Screening Study, and Group (2009) Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. <i>BMJ (Clinical research ed.)</i> 338, b2307	Study did not assess risk factors associated with aneurysm rupture or growth. Instead, unadjusted Cox regression was used to compare deaths related to abdominal aortic aneurysm and all-cause mortality between individuals in two randomised groups.
37	Thompson A R, Golledge J, Cooper J A, Hafez H, Norman P E, and Humphries S E (2009) Sequence variant on 9p21 is associated with the presence of abdominal aortic aneurysm disease but does not have an impact on aneurysmal expansion. <i>European Journal of Human Genetics</i> 17(3), 391-394	Case-control: patients with AAA growth were identified and were compared with controls to assess whether they had a variant of the 9p21 chromosome.
38	Thompson Andrew, Cooper Jackie A, Fabricius Michael, Humphries Steve E, Ashton Hilary A, and Hafez Hany (2010) An analysis of drug modulation of	No data of interest: aneurysm growth rates were calculated by linear regression analysis. This is a different outcome to that specified in the review protocol: "radiological

No.	Study	Reason for exclusion
	abdominal aortic aneurysm growth through 25 years of surveillance. Journal of vascular surgery 52(1), 55-61.e2	diagnosis of abdominal aortic aneurysm expansion; single test within a study”
39	Urbonavicius S, Urbonaviciene G, Honore B, Henneberg E W, Vorum H, and Lindholt J S (2008) Potential circulating biomarkers for abdominal aortic aneurysm expansion and rupture--a systematic review. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 36(3), 273-2	Systematic review which aimed to summarise evidence on various systemic biomarkers for aneurysm rupture or expansion. Individual studies were assessed to determine whether they met inclusion criteria for this NICE review.
40	Vande Geest, Jonathan P, Wang David H. J, Wisniewski Stephen R, Makaroun Michel S, and Vorp David A (2006) Towards a noninvasive method for determination of patient-specific wall strength distribution in abdominal aortic aneurysms. Annals of biomedical engineering 34(7), 1098-106	Study did not assess risk factors associated with aneurysm growth or rupture. Instead investigators developed a statistical model for estimating AAA wall strength.
41	Vardulaki K A, Prevost T C, Walker N M, Day N E, Wilmink A B. M, Quick C R. G, Ashton H A, and Scott R A. P (1998) Growth rates and risk of rupture of abdominal aortic aneurysms. British Journal of Surgery 85(12), 1674-1680	Secondary data analysis of 2 population-based screening programmes. Multivariate analysis was not performed to assess risk factors associated with aneurysm growth or rupture.
42	Vardulaki K A, Walker N M, Day N E, Duffy S W, Ashton H A, and Scott R A. P (2000) Quantifying the risks of hypertension, age, sex and smoking in patients with abdominal aortic aneurysm. British Journal of Surgery 87(2), 195-200	Study employed a mixed methods design. Population-based screening (a cross-sectional approach) was used to assess the prevalence of AAAs. A prospective observational approach was used to assess aneurysm growth rates; however, multivariate analysis-regression was not performed.
43	Wanhainen Anders, Mani Kevin, Vorkapic Emina, De Basso , Rachel , Bjorck Martin, Lanne Toste, and Wagsater Dick (2017) Screening of circulating microRNA biomarkers for prevalence of abdominal aortic aneurysm and aneurysm growth. Atherosclerosis 256, 82-88	The study had a sample size of less than 500 participants (n=217).
44	Xiong Jiang, Wu Zhongyin, Chen Chen, Wei Yingqi, and Guo Wei (2016) Association between diabetes and prevalence and growth rate of abdominal aortic aneurysms: A meta-analysis. International journal of cardiology 221, 484-95	Systematic review which included studies that employed multiple study designs. Individual studies were assessed to establish if they met criteria for inclusion in this NICE review.

Economic studies

No full text papers were retrieved. All studies were excluded at review of titles and abstracts.

Appendix H – Glossary

Abdominal Aortic Aneurysm (AAA)

A localised bulge in the abdominal aorta (the major blood vessel that supplies blood to the lower half of the body including the abdomen, pelvis and lower limbs) caused by weakening of the aortic wall. It is defined as an aortic diameter greater than 3 cm or a diameter more than 50% larger than the normal width of a healthy aorta. The clinical relevance of AAA is that the condition may lead to a life threatening rupture of the affected artery. Abdominal aortic aneurysms are generally characterised by their shape, size and cause:

- **Infrarenal AAA:** an aneurysm located in the lower segment of the abdominal aorta below the kidneys.
- **Juxtarenal AAA:** a type of infrarenal aneurysm that extends to, and sometimes, includes the lower margin of renal artery origins.
- **Suprarenal AAA:** an aneurysm involving the aorta below the diaphragm and above the renal arteries involving some or all of the visceral aortic segment and hence the origins of the renal, superior mesenteric, and celiac arteries, it may extend down to the aortic bifurcation.

Abdominal compartment syndrome

Abdominal compartment syndrome occurs when the pressure within the abdominal cavity increases above 20 mm Hg (intra-abdominal hypertension). In the context of a ruptured AAA this is due to the mass effect of a volume of blood within or behind the abdominal cavity. The increased abdominal pressure reduces blood flow to abdominal organs and impairs pulmonary, cardiovascular, renal, and gastro-intestinal function. This can cause multiple organ dysfunction and eventually lead to death.

Cardiopulmonary exercise testing

Cardiopulmonary Exercise Testing (CPET, sometimes also called CPX testing) is a non-invasive approach used to assess how the body performs before and during exercise. During CPET, the patient performs exercise on a stationary bicycle while breathing through a mouthpiece. Each breath is measured to assess the performance of the lungs and cardiovascular system. A heart tracing device (Electrocardiogram) will also record the hearts electrical activity before, during and after exercise.

Device migration

Migration can occur after device implantation when there is any movement or displacement of a stent-graft from its original position relative to the aorta or renal arteries. The risk of migration increases with time and can result in the loss of device fixation. Device migration may not need further treatment but should be monitored as it can lead to complications such as aneurysm rupture or endoleak.

Endoleak

An endoleak is the persistence of blood flow outside an endovascular stent - graft but within the aneurysm sac in which the graft is placed.

- Type I – Perigraft (at the proximal or distal seal zones): This form of endoleak is caused by blood flowing into the aneurysm because of an incomplete or ineffective seal at either end of an endograft. The blood flow creates pressure within the sac and significantly increases the risk of sac enlargement and rupture. As a result, Type I endoleaks typically require urgent attention.
- Type II – Retrograde or collateral (mesenteric, lumbar, renal accessory): These endoleaks are the most common type of endoleak. They occur when blood bleeds into the sac from small side branches of the aorta. They are generally considered benign because they are usually at low pressure and tend to resolve spontaneously over time without any need for intervention. Treatment of the endoleak is indicated if the aneurysm sac continues to expand.
- Type III – Midgraft (fabric tear, graft dislocation, graft disintegration): These endoleaks occur when blood flows into the aneurysm sac through defects in the endograft (such as graft fractures, misaligned graft joints and holes in the graft fabric). Similarly to Type I endoleak, a Type III endoleak results in systemic blood pressure within the aneurysm sac that increases the risk of rupture. Therefore, Type III endoleaks typically require urgent attention.
- Type IV– Graft porosity: These endoleaks often occur soon after AAA repair and are associated with the porosity of certain graft materials. They are caused by blood flowing through the graft fabric into the aneurysm sac. They do not usually require treatment and tend to resolve within a few days of graft placement.
- Type V – Endotension: A Type V endoleak is a phenomenon in which there is continued sac expansion without radiographic evidence of a leak site. It is a poorly understood abnormality. One theory that it is caused by pulsation of the graft wall, with transmission of the pulse wave through the aneurysm sac to the native aneurysm wall. Alternatively it may be due to intermittent leaks which are not apparent at imaging. It can be difficult to identify and treat any cause.

Endovascular aneurysm repair

Endovascular aneurysm repair (EVAR) is a technique that involves placing a stent –graft prosthesis within an aneurysm. The stent-graft is inserted through a small incision in the femoral artery in the groin, then delivered to the site of the aneurysm using catheters and guidewires and placed in position under X-ray guidance.

- Conventional EVAR refers to placement of an endovascular stent graft in an AAA where the anatomy of the aneurysm is such that the ‘instructions for use’ of that particular device are adhered to. Instructions for use define tolerances for AAA anatomy that the device manufacturer considers appropriate for that device. Common limitations on AAA anatomy are infrarenal neck length (usually >10mm), diameter (usually ≤30mm) and neck angle relative to the main body of the AAA
- Complex EVAR refers to a number of endovascular strategies that have been developed to address the challenges of aortic proximal neck fixation associated with complicated aneurysm anatomies like those seen in juxtarenal and suprarenal AAAs. These strategies include using conventional infrarenal aortic stent grafts outside their ‘instructions for use’, using physician-modified endografts, utilisation of customised fenestrated endografts, and employing snorkel or chimney approaches with parallel covered stents.

Goal directed therapy

Goal directed therapy refers to a method of fluid administration that relies on minimally invasive cardiac output monitoring to tailor fluid administration to a maximal cardiac output or other reliable markers of cardiac function such as stroke volume variation or pulse pressure variation.

Post processing technique

For the purpose of this review, a post-processing technique refers to a software package that is used to augment imaging obtained from CT scans, (which are conventionally presented as axial images), to provide additional 2- or 3-dimensional imaging and data relating to an aneurysm's, size, position and anatomy.

Permissive hypotension

Permissive hypotension (also known as hypotensive resuscitation and restrictive volume resuscitation) is a method of fluid administration commonly used in people with haemorrhage after trauma. The basic principle of the technique is to maintain haemostasis (the stopping of blood flow) by keeping a person's blood pressure within a lower than normal range. In theory, a lower blood pressure means that blood loss will be slower, and more easily controlled by the pressure of internal self-tamponade and clot formation.

Remote ischemic preconditioning

Remote ischemic preconditioning is a procedure that aims to reduce damage (ischaemic injury) that may occur from a restriction in the blood supply to tissues during surgery. The technique aims to trigger the body's natural protective functions. It is sometimes performed before surgery and involves repeated, temporary cessation of blood flow to a limb to create ischemia (lack of oxygen and glucose) in the tissue. In theory, this "conditioning" activates physiological pathways that render the heart muscle resistant to subsequent prolonged periods of ischaemia.

Tranexamic acid

Tranexamic acid is an antifibrinolytic agent (medication that promotes blood clotting) that can be used to prevent, stop or reduce unwanted bleeding. It is often used to reduce the need for blood transfusion in adults having surgery, in trauma and in massive obstetric haemorrhage.